iShares Biotechnology ETF
463 hedge funds and large institutions have $4.63B invested in iShares Biotechnology ETF in 2016 Q3 according to their latest regulatory filings, with 87 funds opening new positions, 146 increasing their positions, 137 reducing their positions, and 44 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding in top 10
Funds holding in top 10: →
more capital invested
Capital invested by funds: $ → $
more funds holding
Funds holding: →
7% more repeat investments, than reductions
Existing positions increased: 146 | Existing positions reduced: 137
47% less call options, than puts
Call options by funds: $650M | Put options by funds: $1.24B
Holders
463
Holding in Top 10
25
Calls
$650M
Puts
$1.24B
Top Buyers
| 1 | +$315M | |
| 2 | +$140M | |
| 3 | +$87.2M | |
| 4 |
CI
Clal Insurance
Tel-Aviv,
Israel
|
+$66.3M |
| 5 |
MIFH
Migdal Insurance & Financial Holdings
Petach Tikva,
Israel
|
+$51.9M |
Top Sellers
| 1 | -$117M | |
| 2 | -$110M | |
| 3 | -$57.8M | |
| 4 |
Two Sigma Advisers
New York
|
-$41.5M |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$26.8M |